New Delhi: The human trials of Covaxin, India’s first coronavirus vaccine, are all set to begin at All India Institute of Medical Sciences (AIIMS) on Monday. The ethics committee has given its nod.
AIIMS is among the twelve sites selected by Indian Council of Medical Research (ICMR) for conducting Phase I and II human trials.
The clinical trial will be conducted on healthy volunteers with no comorbid condition and without a history of coronavirus infection. They should be in the age group of 18-55 years. The vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
AIIMS will first screen the individuals and evaluate the health conditions before starting to vaccinate them. The screening will start from Monday.
Covaxin was developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV).